FDA Approved: XOFIGO — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved a supplemental application for XOFIGO (radium Ra-223 dichloride) from Bayer HealthCare Pharmaceuticals, updating its labeling/indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Xofigo (radium-223 dichloride)

Snippet

SUPPL AP for XOFIGO (RADIUM RA 223 DICHLORIDE)